Lindsay A Williams1,2, Aubrey K Hubbard1, Michael E Scheurer3, Logan G Spector1,2, Jenny N Poynter1,2. 1. Division of Epidemiology & Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA. 2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA. 3. Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
Abstract
BACKGROUND: Central nervous system (CNS) tumours comprise 20% of childhood cancers worldwide. Whether childhood CNS tumour incidence has increased over time across geographic regions remains to be explored. METHODS: We identified CNS cancers in the Cancer in Five Continents (CI5) data and estimated age standardized incidence rates (ASRs; cases/million children) and 95% confidence intervals (95% CI), male-to-female incidence rate ratios (IRR; 95% CI) and average annual percent change in incidence (AAPC; 95% CI) by geographic region for children aged 0-19 years where data were available using Poisson regression and generalized estimating equations (GEE). Cancers included: astrocytic tumours, medulloblastoma, ependymal, oligodendroglial and mixed glioma, glioma of uncertain origin, and other embryonal tumours. Geographic regions were defined using the United Nations geoscheme. RESULTS: There were 56 468 CNS cancers included in the study. ASRs were highest for astrocytic tumours globally in 2012 (ASR: 5.83; 95% CI: 5.68-5.99). Globally, all cancers exhibited a male excess in incidence. Regionally, only medulloblastoma had a consistently elevated male-to-female IRR at 1.4-2.2. Globally, incidence decreased for astrocytic tumours in GEE models (AAPC: -1.66; 95% CI: -3.04 to -0.26) and increased for medulloblastoma (AAPC 0.66; 95% CI: 0.19-1.14), ependymal tumours (AAPC: 1.49; 95% CI: 1.49; 95%: 0.69-2.30), glioma of uncertain origin (AAPC: 4.76; 95% CI: 1.17-1.14) and other embryonal tumours (AAPC: 3.58; 95% CI: 2.03-5.15). Regional variation in incidence trends was observed. Countries moving from lower to higher Human Development Index (HDI) over time did not appear to drive observed incidence trends. CONCLUSIONS: Epidemiologic and molecular studies on underlying mechanisms for changes in the global incidence of CNS tumours are necessary.
BACKGROUND:Central nervous system (CNS) tumours comprise 20% of childhood cancers worldwide. Whether childhood CNS tumour incidence has increased over time across geographic regions remains to be explored. METHODS: We identified CNS cancers in the Cancer in Five Continents (CI5) data and estimated age standardized incidence rates (ASRs; cases/million children) and 95% confidence intervals (95% CI), male-to-female incidence rate ratios (IRR; 95% CI) and average annual percent change in incidence (AAPC; 95% CI) by geographic region for children aged 0-19 years where data were available using Poisson regression and generalized estimating equations (GEE). Cancers included: astrocytic tumours, medulloblastoma, ependymal, oligodendroglial and mixed glioma, glioma of uncertain origin, and other embryonal tumours. Geographic regions were defined using the United Nations geoscheme. RESULTS: There were 56 468 CNS cancers included in the study. ASRs were highest for astrocytic tumours globally in 2012 (ASR: 5.83; 95% CI: 5.68-5.99). Globally, all cancers exhibited a male excess in incidence. Regionally, only medulloblastoma had a consistently elevated male-to-female IRR at 1.4-2.2. Globally, incidence decreased for astrocytic tumours in GEE models (AAPC: -1.66; 95% CI: -3.04 to -0.26) and increased for medulloblastoma (AAPC 0.66; 95% CI: 0.19-1.14), ependymal tumours (AAPC: 1.49; 95% CI: 1.49; 95%: 0.69-2.30), glioma of uncertain origin (AAPC: 4.76; 95% CI: 1.17-1.14) and other embryonal tumours (AAPC: 3.58; 95% CI: 2.03-5.15). Regional variation in incidence trends was observed. Countries moving from lower to higher Human Development Index (HDI) over time did not appear to drive observed incidence trends. CONCLUSIONS: Epidemiologic and molecular studies on underlying mechanisms for changes in the global incidence of CNS tumours are necessary.
Authors: Eva Steliarova-Foucher; Charles Stiller; Peter Kaatsch; Franco Berrino; Jan-Willem Coebergh; Brigitte Lacour; Max Parkin Journal: Lancet Date: 2004 Dec 11-17 Impact factor: 79.321
Authors: Fonnet E Bleeker; Saskia M J Hopman; Johannes H M Merks; Cora M Aalfs; Raoul C M Hennekam Journal: Neuropediatrics Date: 2014-02-17 Impact factor: 1.947
Authors: Kimberly J Johnson; Jennifer Cullen; Jill S Barnholtz-Sloan; Quinn T Ostrom; Chelsea E Langer; Michelle C Turner; Roberta McKean-Cowdin; James L Fisher; Philip J Lupo; Sonia Partap; Judith A Schwartzbaum; Michael E Scheurer Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-09-05 Impact factor: 4.254
Authors: Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman Journal: Neuro Oncol Date: 2012-09-05 Impact factor: 12.300
Authors: Eva Steliarova-Foucher; Murielle Colombet; Lynn A G Ries; Florencia Moreno; Anastasia Dolya; Freddie Bray; Peter Hesseling; Hee Young Shin; Charles A Stiller Journal: Lancet Oncol Date: 2017-04-11 Impact factor: 41.316
Authors: Pablo Monterroso; Kristin J Moore; Jeannette M Sample; Natali Sorajja; Allison Domingues; Lindsay A Williams Journal: Cancer Epidemiol Date: 2021-12-09 Impact factor: 2.984
Authors: Austin L Brown; Pagna Sok; Michael E Scheurer; Karen R Rabin; Erin L Marcotte; Douglas S Hawkins; Logan G Spector; Philip J Lupo Journal: Cancer Date: 2022-04-28 Impact factor: 6.921
Authors: Logan G Spector; Aubrey K Hubbard; Brandon J Diessner; Mitchell J Machiela; Beau R Webber; Joshua D Schiffman Journal: Int J Cancer Date: 2021-05-17 Impact factor: 7.316